Alnylam's third-quarter net product revenue was $1.29 billion, up 52% year over year, driven by transthyretin revenue growth of 59% to $1.15 billion. However, management now expects full-year TTR revenue to be at the low end of its $4.2 billion-$4.5 billion guidance. Shares plummeted 25% on Oct. 29.
Alnylam's Nobel-prize-winning technology and massive intellectual property in RNA interference helped the firm create an entirely new class of therapeutics for difficult to treat diseases.
Alnylam's valuation rests on its ability to maintain six-figure pricing and payers' willingness to continue reimbursement, which could be affected by shifts in healthcare drug policy.
|
Metric
|
ALNY
|
IONS
|
INCY
|
|---|---|---|---|
Price/Earnings (Normalized) | 7.95 | — | 49.42 |
Price/Book Value | 5.98 | 15.12 | 4.44 |
Price/Sales | 4.42 | 7.49 | 4.25 |
Price/Cash Flow | 15.80 | — | 22.89 |
|
Metric
|
ALNY
|
IONS
|
INCY
|
|---|---|---|---|
Quick Ratio | 2.26 | 6.70 | 3.54 |
Current Ratio | 2.48 | 7.89 | 3.84 |
Interest Coverage | 3.22 | −5.82 | 283.92 |
|
Metric
|
ALNY
|
IONS
|
INCY
|
|---|---|---|---|
Return on Assets (Normalized) | 50.54% | −12.57% | 9.15% |
Return on Equity (Normalized) | 204.12% | −75.28% | 11.94% |
Return on Invested Capital (Normalized) | 112.35% | −14.91% | 10.07% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|W%!RQLq | LOCK|XgK< | $139B | |||
| Moderna Inc
MRNA
| LOCK|&ZgpxJ$ | LOCK|RXF | $103B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$@^>?KX | LOCK|z<^$s | $96B | |||
| argenx SE ADR
ARGX
| LOCK|lP@$%V | LOCK|r% | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>&@?Hv | LOCK|#Pz | $45B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%gR<v@$^ | LOCK|D$GR | $30B | |||
| Incyte Corp
INCY
| LOCK|scXzcv | LOCK|!& | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|G?Jy&>% | LOCK|w&^ | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|BcmD<%v | LOCK|#$t | $15B |
United States